Filter
1238
Featured
79
136
Language
Document type
797
94
92
66
59
35
34
31
11
5
5
5
4
Countries
107
70
35
31
30
28
22
22
21
19
18
15
14
14
14
12
12
12
11
11
11
11
11
10
10
9
9
9
8
8
8
8
6
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
339
94
18
15
9
7
5
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij
...
The Lancet Global Health January 24, 2022
Laboratory Safety Handbook. Global edition
Las pruebas de cultivo y sensibilidad a fármacos son necesarias especialmente para los pacientes con riesgo de tuberculosis resistente a los medicamentos y para vigilar su respuesta al tratamiento. Si bien el cultivo y las pruebas de sensibilidad son ca
...
his Framework begins with a desired future scenario and considers actions and interventions necessary to get there. It advocates for holistic view to address tuberculosis. The Framework revisits challenges and actions in four layers: TB specific; challenges in health systems that influence TB care;
...
Estas directrices sustituyen a los anteriores documentos de política de la OMS sobre el manejo de la ILTB en las personas con la infección por el VIH, los contactos del hogar de personas con TB y otros grupos de riesgo. Las Directrices unificadas de la OMS sobre la tuberculosis: Tratamiento preven
...
The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB
N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535
Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)
Tuberculosis (TB) is the deadliest infectious disease in most low- and middle-income countries, claiming more than 4,000 lives each day. The unprecedented COVID-19 pandemic has seriously impacted people with pre-existing health conditions. People with TB are usually more vulnerable to other infectio
...
Tuberculosis (TB)
recommended
MEDBOX Issue Brief no. 19: World TB Day: Invest to end TB. Save Lives
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama
...
WHO operational handbook on tuberculosis Module 5: Management of tuberculosis in children and adolescents
recommended
The practical guidance in the operational handbook aims to inform the development or revision of national policies and related implementation guidance on the management of TB in children and adolescents under programmatic circumstances and at different levels of the health system. The operational ha
...
Accessed on 13.05.2022
The Covid-19 pandemic has become Chile’s most consequential public health challenge in a century. Chile’s measures included guidance regarding, among other items, education, health (sick leaves, diagnoses, hospital capacity, partial and spatially targeted lockdowns), ma
...
